Clinical Trial Update: Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating cardiac safety with repeated doses of dihydroartemisinin-piperaquine for mass malaria treatment campaigns has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Dihydroartemisinin-piperaquine (dihydroartemisinin-piperaquine)

Snippet

Sponsor: Lihir Medical Centre | Conditions: Malaria | Phase 3 | Status: COMPLETED